{"slug":"radioligand","tag":"radioligand","variants":["radioligand"],"description":"No description yet","count":5,"kinds":{"person":5},"related":[{"slug":"neuroendocrine","tag":"neuroendocrine","shared":2},{"slug":"prostate","tag":"prostate","shared":2},{"slug":"trialist","tag":"trialist","shared":2},{"slug":"australia","tag":"australia","shared":1},{"slug":"canada","tag":"canada","shared":1},{"slug":"germany","tag":"germany","shared":1},{"slug":"nuclear-medicine","tag":"nuclear medicine","shared":1}],"records":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","tldr":"Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer."},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","tldr":"Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics."},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours."},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","tldr":"Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours."},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","tldr":"Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes."}]}